tirzepatide for ckd GLP therapies have established themselves as kidney-protective in type 2 diabetes and high risk of kidney disease. This new post-hoc analysis of SURPASS-CVOT's kidney outcomes shows greater kidney protection with (#mounjaro) Utilization Trends of Dual GIP/GLP-1

Description

Why this matters for weight loss: When food stays in your stomach longer, you feel satisfied for an extended period

This is where appetite changes typically begin for most users

In people with obesity without T2DM, tirzepatide 10 and 15 mg for 72 weeks resulted in 35.0% to 39.7% achieving 25% WL

Presse Med 2001;30:1695-700

had a serum calcitonin level (at visit 1) of 20 ng l 1 , if eGFR 60 ml min 1 1.73 m 2 35 ng l 1 , if eGFR 2 weeks or 14 days) systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, intra-articular or inhaled preparations) or had evidence of a substantial, active autoimmune abnormality (for example, lupus or rheumatoid arthritis) that had required (within the past 3 months) or was likely to require, in the opinion of the investigator, concurrent treatment with systemic glucocorticoids (excluding topical, intraocular, intranasal, intra-articular or inhaled preparations) during the course of the study 33